Nirvana Life Sciences Inc.

Equities

NIRV

CA6546521064

Biotechnology & Medical Research

Delayed Canadian Securities Exchange 07:50:28 01/05/2024 pm IST 5-day change 1st Jan Change
0.05 CAD 0.00% Intraday chart for Nirvana Life Sciences Inc. 0.00% +150.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023 CI
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc. CI
Nirvana Life Sciences Inc. entered into a letter of intent to acquire Medsmart Dispensary Inc. for $0.13 million. CI
Nirvana Life Sciences Inc. announced that it has received funding CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023 CI
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022 CI
Nirvana Life Sciences Agrees to Buy Licensed Distributor of Patented, Herbal Treatment for Opiate Addiction MT
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022 CI
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds CI
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt CI
Nirvana Life Sciences Inc. Announces Executive Changes CI
Nirvana Life Sciences Inc. Announces License for A Delivery System for Psychedelic APIs CI
Nirvana Life Sciences Announces Approval to Build Vancouver Facility from Health Canada CI
Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug Compound CI
Nirvana Life Sciences Announces Patent Filing CI
Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study CI
Nirvana Life Sciences Inc. announced that it has received CAD 0.15 million in funding from ThreeD Capital Inc. CI
Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory Board CI
Nirvana Life Sciences Inc. Announce Further Progress with Development of Its Vancouver Research and Development Facility CI
Nirvana Life Sciences Inc. Reports Progress with Health Canada Dealer's License Application and Facility Development CI
Chart Nirvana Life Sciences Inc.
More charts
Nirvana Life Sciences Inc. is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The Company has selected two products for its first phase of development: a one-per-day slow release gel cap that assists transition from opioids to non-addictive pain relief therapies, and a one-per-day slow release gel cap that delivers non-addictive pain relief. Any number of therapeutic medicines and products are created from its formulations. The Company is also engaged in growing several genera and species of fungi (including rare and hybrid varieties) with a batch consistency.
More about the company
  1. Stock Market
  2. Equities
  3. NIRV Stock
  4. News Nirvana Life Sciences Inc.
  5. Nirvana Life Sciences Agrees to Buy Licensed Distributor of Patented, Herbal Treatment for Opiate Addiction
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW